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Summary
Background: The surgical treatment of patent ductus arteriosus is indicated when the clinical intervention fails. However, 
this treatment may present some complications.
Objective: To analyze clinical and surgical aspects involved in the treatment of patent ductus arteriosus in the premature 
newborn.
Methods: Twenty-two premature newborns, submitted to surgical treatment for patent ductus arteriosus from January 
2000 to June 2006, were evaluated. Of the 22 newborns, 77.3% were females, mean birth weight was 952.5 g and the 
mean gestational age was 27 weeks. The use of vasoactive drugs, indomethacin, echocardiographic parameters and 
complications were evaluated in the pre- and postoperative periods.
Results: In this sample, 59.1% of the patients needed intratracheal intubation at birth, 77.3% needed surfactants and 
59.1% used preoperative vasoactive drugs. The mean number of indomethacin doses was 3.43, with dose ranging from 
0.10 to 0.25 mg/Kg/day. The mean caliber of the patent ductus arteriosus was 1.96 mm.  The surgical procedure was 
carried out through extrapleural access in 59.1% of the patients; the mean time of postoperative intubation was 30.9 
days and 50% of the patients used postoperative vasoactive drugs. There were 18.1% of postoperative complications 
(non-fatal postoperative complications).
Conclusion: More than 50% of the patients needed intratracheal intubation at birth, surfactant use and vasoactive 
drugs in the preoperative period. There was a higher prevalence of the extrapleural approach during surgery. In the 
postoperative period, there was a lower need for vasoactive drugs and there were no deaths related to the surgical 
procedure. (Arq Bras Cardiol 2008; 90(5): 316-319)
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detriment to the systemic perfusion, due to the left-right shunt4. 
This hemodynamic alteration causes a left ventricular overload, 
myocardial dysfunction and respiratory failure4. Additionally, 
severe complications that are associated or concomitant to PDA 
are necrotizing enterocolitis, renal failure, bronchopulmonary 
dysplasia and intraventricular hemorrhage4-10.
The clinical therapy of PDA is mainly based on the 
administration of indomethacin, an agent that is a prostaglandin-
synthesis inhibitor, associated to fluid restriction and diuretics4. 
However, in situations where the PDA is refractory to the 
clinical management, its surgical ligation is indicated, aiming 
at attenuating its hemodynamic complications4,11-13. Although 
this surgical intervention presents satisfactory results, it is not 
complication-free. Therefore, the aim of this study is to show 
the clinical and surgical aspects involved in the treatment of 
PDA in premature newborn infants.
Methods
A retrospective analysis of the clinical and surgical aspects 
of 22 newborn infants, with gestational age below 32 weeks, 
Introduction
The arterial canal functions as a vital arterial conduit during 
intrauterine life that is vital for the satisfactory development 
of the fetus, as it diverts more than half of the cardiac output 
for the systemic and the umbilical-placental circulation1,2. At 
birth, in the presence of the blood rise of the oxygen pressure, 
a constriction of this canal occurs, concomitantly with the 
dilation of the pulmonary circulation, thus establishing a new 
circulatory pattern in the newborn (NB)1,2.
However, in premature NB, this mechanism of arterial 
canal closing does not occur in 50% of the cases, resulting in a 
congenital cardiac defect called patent ductus arteriosus (PDA)1-
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who were submitted to the surgical treatment of patent ductus 
arteriosus during January 2000 to June 2006 was carried out. 
These patients were originally from the Federal University of 
São Paulo – Hospital São Paulo and Hospital Santa Catarina. 
All NB that presented other concomitant heart diseases and/or 
incomplete medical files were excluded. 
Of the patients that were included in the study, 5 (22.7%) 
were males and 17 (77.3%) were females; the mean gestational 
age at birth was 27 weeks (ranging from 23 to 32 weeks) and 
mean weight was 952.5 g (ranging from 485 to 1,765 g). Birth 
by normal delivery had occurred in 4 (18.1%) cases and the 
diagnosis of PDA was carried out clinically in 8 (36.3%) and 
by echocardiogram in 14 (63.7%) cases.
The mean diameter of the arterial canal was 1.96 mm (0.2 
– 3.2 mm). Of all the patients, only 4 (18.1%) did not undergo 
the clinical management with indomethacin, considering that 
their clinical condition required immediate surgical approach. 
The mean number of indomethacin applications was 3.4, with 
the dose varying from 0.1 to 0.25 mg/Kg/day, administered 
orally. However, this drug was not effective in any of the cases 
of this surgical series, regarding the closing of the canal. 
Based on the reviewed data, information on the pre-, intra- 
and postoperative periods of each patient were obtained. 
These data included the need for orotracheal intubation (OTI) 
and ventilation parameters, surfactant administration, use of 
vasoactive drugs, access pathway and surgical technique, 
postoperative complications, re-operations, hospital stay 
duration and deaths. 
All these reviewed parameters were evaluated under the 
aspect of analyses of prevalence.
Results
The surgical procedure was carried out exclusively at the 
surgical center, with the patient under general anesthesia. 
The surgical access of choice was the left posterolateral 
thoracotomy and the intrapleural approach was used in 9 
(40.9%0 of the patients, with a mean operation time of 58 
minutes (20 to 120 minutes). In this series, only one patient 
was submitted to the arterial canal clamping, whereas the 
others were submitted to its ligation. 
The complications observed in this series were 
bronchopulmonary dysplasia in 2 patients, congestive heart 
failure and surgical wound infection in 1 patient. No cases 
of renal failure or necrotizing enterocolitis were observed; 
however, all patients presented intraventricular hemorrhage, 
although there were no consequences for the central nervous 
system. Three deaths, which were unrelated to the surgical 
procedure, occurred due to septic shock with a pulmonary 
infectious source and 1 patient needed to be re-operated 
due to clamping loosening. The mean time of OTI during 
the hospital stay was 30.9 days (1 to 91 days) and the mean 
duration of hospital stay was 89 days (17 to 332 days). The 
chest drain in the patients with an intrapleural approach was 
removed after a mean time of 1.8 days (1 to 2 days) after 
the surgery. Complementary data of the results are shown in 
charts 1 and 2.
Discussion
The decrease in the mortality rates of premature, low-
weight newborn infants is one of the milestones of modern 
Medicine and reflects the development and the quality of 
assistance given during the pregnancy and labor management. 
It is known that a premature patient, even when free of other 
comorbidities, presents neuropsychomotor development 
(NPMD) retardation, which requires a stringent follow-up by 
the healthcare team14. 
However, it is also known that this group of patients 
presents an increased risk of malformations and congenital 
diseases, mainly cardiovascular ones. The study by Rivera 
et al15, published in 2007, shows a prevalence of congenital 
heart disease of 13.2:1,000 live births, which is higher 
than that reported by Guitti16, in 2000, of 5.5:1,000 live 
births. In premature infants, the presence of heart disease 
significantly impairs the NPMD, in addition to failure to 
thrive. It is under these considerations that one must analyze 
the patent ductus arteriosus. 
Our cohort shows a predominance of the female sex 
977.3%), which corresponds with the prevalence of PDA 
described in the literature. Due to lung immaturity, surfactant 
was administered to 77.3% of the patients and OTI was carried 
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out in 59.1% of the cases. It is known that PDA influences 
adequate pulmonary function; however, Van Woerkom et al, 
in a study of low-weight NB infants submitted to PDA ligation, 
did not observe short-term improvement in the patients’ 
ventilation parameters17. This fact was confirmed by Carboni 
& Ringel18, Farstad & Bratlid19 in their results.
The mean diameter of the PDA was 1.96 mm. Literature 
data show that PDA severity can be expressed as a ratio 
between the sizes of the left atrium and aortic root > 1.47 or 
a transversal diameter of the largest canal > 1.5 mm, in the 
presence of a left-right shunt20,21.
Therefore, most of the patients in the present study 
presented disease with important clinical and/or hemodynamic 
implication. However, the patients with a transversal diameter 
< 1.5 mm, although they did not have severe PDA, according 
to the aforementioned criteria, presented unfavorable clinical 
conditions, which also represented high risk.
The number of doses of indomethacin used in this study is 
in accordance with the doses administered in other studies4,22. 
However, the closing of the arterial canal was not observed 
following this treatment protocol. This might be explained 
by the fact that, in the present study, indomethacin was 
administered orally, which has been proven to be less effective 
than the intravenous administration of the drug.
Additionally, this drug has also been studied as prophylaxis 
for intraventricular hemorrhage in patients with PDA23,24. 
A meta-analysis designed by Fowlie et al, in 200314, 
showed the efficacy of indomethacin in preventing this 
complication. Nevertheless, whether the prophylactic effect 
in intraventricular hemorrhage is secondary to the closing of 
PDA by indomethacin is debatable22.
All of the patients presented intraventricular hemorrhage, a 
fact that, in literature, is associated to the presence of PDA4-10. 
However, this fact might be simply due to prematurity itself, 
as this group of patients is more susceptible to this type of 
brain injury, regardless of other morbidities14. Hence, we agree 
with the results by Brooks et al22, when they state they did 
not observe an association between PDA and intraventricular 
hemorrhage and other comorbidities.
The surgical procedure was carried out at the surgical center, 
in all patients, without any intercurrent events. It is known that 
this surgical procedure can be performed at the Intensive Care 
Unit (ICU); however, the risks of infection and complications, 
which are inherent to the operative intervention, are in fact 
better controlled and prevented at the surgical center4. Similar 
results were reported by Gould et al4, in a study where the 
authors compared interventions performed at the ICU and 
those performed at the surgical center4. The study results 
were based on the possible complications inherent to the 
transportation of the NB to the operating room. 
In addition to the conventional surgery, i.e., the left 
posterolateral or axillary thoracotomy with canal ligation, 
the thoracoscopy can be employed, as well as the mini-
thoracotomy with extrapleural access and the interventionist 
catheterism25-30.
In fact, the development of several techniques for the 
treatment of PDA aims at attaining the least trauma, risk, cost 
and higher effectiveness than the conventional treatment.
The extrapleural approach is the access of choice for 
reaching the arterial canal, as it prevents the need for 
introducing a chest drain and thus, results in a lower risk of 
postoperative infection and pain. However, considering the 
anatomical variability of the parietal pleural thickness, even 
when the dissection is performed very carefully, many times 
it is not possible to preserve its integrity and the intrapleural 
access is followed. 
The chest drain, when employed, remained in our patients 
for a mean period of 1.8 days. This is in accordance with the 
information reported by Gould et al4. However, these authors 
do not discuss the type of surgical access was employed, 
whether it was intra or extrapleural. 
Among the observed postoperative complications, the 
main one was bronchopulmonary dysplasia, which presented 
as a consequence of the PDA, although some studies do not 
show such association4,20. The deaths described were not due 
to the surgical procedure, as they occurred 30 days after the 
intervention, but they reflect the severity of the picture in the 
newborn. The mortality rate of 13.6% is in accordance with 
that reported in literature, with similar data4,20. 
In summary, the data presented here show the experience 
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of our Service in the treatment of PDA, explicating the clinical 
and surgical management. In fact, the inclusion criteria are 
restricted and well-delimited, so if anything is lost regarding 
the number of patients, it is gained in terms of sample 
homogeneity. However, it is important to mention that, as 
demonstrated by our experience, when treating a newborn 
patient with PDA, one must keep in mind that a prolonged 
postoperative period should be expected, with a mean 
intubation time > 3 weeks and, therefore, with a higher risk 
of hospital infection and sepsis. 
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